{
    "Trade/Device Name(s)": [
        "Afinion\u2122 HbA1c",
        "Afinion\u2122 2",
        "Alere Afinion\u2122 AS100 Analyzer"
    ],
    "Submitter Information": "Abbott Diagnostics Technologies AS",
    "510(k) Number": "K214117",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171650",
        "K151809",
        "K050574",
        "K110056"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JQT"
    ],
    "Summary Letter Date": "May 3, 2023",
    "Summary Letter Received Date": "May 3, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.2400"
    ],
    "Regulation Name(s)": [
        "Glycosylated Hemoglobin Assay"
    ],
    "Analyte Class(es)": [
        "hematology",
        "chemistry"
    ],
    "Analyte(s)": [
        "Glycated hemoglobin",
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Venous whole blood",
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Afinion\u2122 AS100 Analyzer",
        "Afinion\u2122 2 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Boronate affinity assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Accessory",
        "Control",
        "Cartridge",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Afinion\u2122 HbA1c assay with modified labeling for point-of-care quantitative measurement of hemoglobin A1c in whole blood using Afinion\u2122 analyzers",
    "Indications for Use Summary": "Quantitative determination of glycated hemoglobin (HbA1c) in venous and capillary human whole blood as a marker of long-term metabolic control in persons with diabetes mellitus, for in vitro diagnostic use with Afinion\u2122 analyzers",
    "fda_folder": "Hematology"
}